Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTX Change and Outcomes in Bone Metastatic Breast Cancer Treated With Zoledronic Acid
ChiCTR-TNC-10000899Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in breast cancer and bone metastases, sponsored by West China Hospital of Sichuan University. Primary endpoints: Skeletal-related events and N-telopeptide of type I collagen (NTX). Started Jul 2010; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on ChiCTR-TNC-10000899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-10000899.